Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib

V. Gregorc; M. Hidalgo; A. Spreafico; G. Cusatis; V. Ludovini; R. G. Ingersoll; S. Marsh; S. M. Steinberg; M. G. Viganò; D. Ghio; E. Villa; A. Sparreboom; S. D. Baker

doi:10.1038/sj.clpt.6100320

Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib

V. Gregorc, M. Hidalgo, A. Spreafico, G. Cusatis, V. Ludovini, R. G. Ingersoll, S. Marsh, S. M. Steinberg, M. G. Viganò, D. Ghio, E. Villa, A. Sparreboom, S. D. Baker

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

The purpose of this study was to evaluate associations between germline epidermal growth factor receptor (EGFR) variants involved in transcriptional regulation and overall survival in white patients with non-small-cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor, gefitinib. Of 175 consecutive patients treated with oral gefitinib (250 mg/day), 170 (median age: 67 years; 72% men) were evaluable for genotyping and survival. Fifty-five patients (33%) had stable disease and 17 (10%) had an objective response. The most common of four haplotypes was G-C (EGFR*1) at the EGFR -216G>T and -191C>A loci (frequency, 0.45). After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015). The results may help identify patients with NSCLC who can benefit from gefitinib treatment.

Original language	English (US)
Pages (from-to)	477-484
Number of pages	8
Journal	Clinical pharmacology and therapeutics
Volume	83
Issue number	3
DOIs	https://doi.org/10.1038/sj.clpt.6100320
State	Published - Mar 2008
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1038/sj.clpt.6100320

Cite this

Gregorc, V., Hidalgo, M., Spreafico, A., Cusatis, G., Ludovini, V., Ingersoll, R. G., Marsh, S., Steinberg, S. M., Viganò, M. G., Ghio, D., Villa, E., Sparreboom, A., & Baker, S. D. (2008). Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clinical pharmacology and therapeutics, 83(3), 477-484. https://doi.org/10.1038/sj.clpt.6100320

Gregorc, V, Hidalgo, M, Spreafico, A, Cusatis, G, Ludovini, V, Ingersoll, RG, Marsh, S, Steinberg, SM, Viganò, MG, Ghio, D, Villa, E, Sparreboom, A & Baker, SD 2008, 'Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib', Clinical pharmacology and therapeutics, vol. 83, no. 3, pp. 477-484. https://doi.org/10.1038/sj.clpt.6100320

@article{b7d3e7c0b19a494d9451ae985f27d074,

title = "Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib",

abstract = "The purpose of this study was to evaluate associations between germline epidermal growth factor receptor (EGFR) variants involved in transcriptional regulation and overall survival in white patients with non-small-cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor, gefitinib. Of 175 consecutive patients treated with oral gefitinib (250 mg/day), 170 (median age: 67 years; 72% men) were evaluable for genotyping and survival. Fifty-five patients (33%) had stable disease and 17 (10%) had an objective response. The most common of four haplotypes was G-C (EGFR*1) at the EGFR -216G>T and -191C>A loci (frequency, 0.45). After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015). The results may help identify patients with NSCLC who can benefit from gefitinib treatment.",

author = "V. Gregorc and M. Hidalgo and A. Spreafico and G. Cusatis and V. Ludovini and Ingersoll, {R. G.} and S. Marsh and Steinberg, {S. M.} and Vigan{\`o}, {M. G.} and D. Ghio and E. Villa and A. Sparreboom and Baker, {S. D.}",

year = "2008",

month = mar,

doi = "10.1038/sj.clpt.6100320",

language = "English (US)",

volume = "83",

pages = "477--484",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib

AU - Gregorc, V.

AU - Hidalgo, M.

AU - Spreafico, A.

AU - Cusatis, G.

AU - Ludovini, V.

AU - Ingersoll, R. G.

AU - Marsh, S.

AU - Steinberg, S. M.

AU - Viganò, M. G.

AU - Ghio, D.

AU - Villa, E.

AU - Sparreboom, A.

AU - Baker, S. D.

PY - 2008/3

Y1 - 2008/3

N2 - The purpose of this study was to evaluate associations between germline epidermal growth factor receptor (EGFR) variants involved in transcriptional regulation and overall survival in white patients with non-small-cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor, gefitinib. Of 175 consecutive patients treated with oral gefitinib (250 mg/day), 170 (median age: 67 years; 72% men) were evaluable for genotyping and survival. Fifty-five patients (33%) had stable disease and 17 (10%) had an objective response. The most common of four haplotypes was G-C (EGFR*1) at the EGFR -216G>T and -191C>A loci (frequency, 0.45). After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015). The results may help identify patients with NSCLC who can benefit from gefitinib treatment.

AB - The purpose of this study was to evaluate associations between germline epidermal growth factor receptor (EGFR) variants involved in transcriptional regulation and overall survival in white patients with non-small-cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor, gefitinib. Of 175 consecutive patients treated with oral gefitinib (250 mg/day), 170 (median age: 67 years; 72% men) were evaluable for genotyping and survival. Fifty-five patients (33%) had stable disease and 17 (10%) had an objective response. The most common of four haplotypes was G-C (EGFR*1) at the EGFR -216G>T and -191C>A loci (frequency, 0.45). After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015). The results may help identify patients with NSCLC who can benefit from gefitinib treatment.

UR - http://www.scopus.com/inward/record.url?scp=39449096577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449096577&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100320

DO - 10.1038/sj.clpt.6100320

M3 - Article

C2 - 17713473

AN - SCOPUS:39449096577

SN - 0009-9236

VL - 83

SP - 477

EP - 484

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 3

ER -

Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this